nach oben

Erschienen in:

01.10.2012 | Colorectal Cancer

Systematic Review of Sentinel Lymph Node Mapping Procedure in Colorectal Cancer

verfasst von: Edwin S. van der Zaag, MD, PhD, Wim H. Bouma, MD, PhD, Pieter J. Tanis, MD, PhD, Dirk T. Ubbink, MD, PhD, Willem A. Bemelman, MD, PhD, Christianne J. Buskens, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinical impact of sentinel lymph node (SN) biopsy in colorectal cancer is still controversial. The aim of our study was to determine the accuracy of this procedure from published data and to identify factors that contribute to the conflicting reports.

Methods

A systematic search of the Medline, Embase, and Cochrane databases up to July 2011 revealed 98 potentially eligible studies, of which 57 were analyzed including 3,934 patients (3,944 specimens).

Results

The pooled SN identification rate was 90.7 % (95 % CI 88.2–93.3), with a significant higher identification rate in studies including more than 100 patients or studies using the ex vivo SN technique. The pooled sensitivity of the SN procedure was 69.6 % (95 % CI 64.7–74.6). Including the immunohistochemical findings increased the pooled sensitivity of SN procedure to 80.2 % (95 % CI 4.7–10.7). Subgroups with significantly higher sensitivity could be identified: ≥4 SNs versus <4 SNs (85.2 vs. 66.3 %, p = 0.003), colon versus rectal cancer (77.6 vs. 65.7 %, p = 0.04), early T1 or T2 versus advanced T3 or T4 carcinomas (93.4 vs. 58.8 %, p = 0.01). Serial sectioning and immunohistochemistry resulted in a mean upstaging of 18.9 % (range 0–50 %). True upstaging defined as micrometastases (pN1mi+) rather than isolated tumor cells (pN0itc+) was 7.7 %.

Conclusions

The SN procedure in colorectal cancer has an overall sensitivity of 70 %, with increased sensitivity and refined staging in early-stage colon cancer. Because the ex vivo SN mapping is an easy technique it should be considered in addition to conventional resection in colon cancer.

American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.

Cohen Am, Kelsen D, Saltz L, Minsky BD, Nelson H, Farouk R, et al. Adjuvant therapy for colorectal cancer. Curr Probl Cancer. 1997;34:601–76.

Mitchell PJ, Ravi S, Grifftiths B, Reid F, Speake D, Midgley C, et al. Multicentre review of lymph node harvest in colorectal cancer: are we understaging colorectal cancer patients? Int J Colorectal Dis. 2009;24:915–21.PubMedCrossRef

Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev. 2008;3:CD005390.PubMed

Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res. 2008;14:7391–96.PubMedCrossRef

Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–66.PubMedCrossRef

Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:311–3.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.PubMedCrossRef

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCrossRef

10.

Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on cancer staging manual. Cancer. 2003;98:2740–1.PubMedCrossRef

11.

Vîlcea ID, Vasile I, Mirea CS, Meşină C, Enache SD, Tenovici M, et al. Sentinel lymph node study in colorectal cancer using serial sectioning and hematoxylin–eosin staining: importance and limitations. Rom J Morphol Embryol. 2011;52:379–83.PubMed

12.

Ceranic MS, Kecmanovic DM, Pavlov MJ, Nale DP, Micev MT, Kovacevic PA, et al. Validation and feasibility of ex vivo sentinel lymph node “mapping” by methylene blue in colorectal cancer. Hepatogastroenterology. 2010;57:1113–8.PubMed

13.

Retter SM, Herrmann G, Schiedeck TH. Clinical value of sentinel node mapping in carcinoma of the colon. Colorectal Dis. 2010;13:855–9.PubMedCrossRef

14.

Finan KR, Lewis JS Jr., Winslow E, Mutch MG, Birnbaum EH, Fleshman JW. Ex vivo sentinel lymph node mapping in patients undergoing proctectomy for rectal cancer. Dis Colon Rectum. 2010;53:243–50.PubMedCrossRef

15.

Sommariva A, Donisi PM, Gnocato B, Vianello R, Stracca Pansa V, Zaninotto G. Factors affecting false-negative rates on ex vivo sentinel lymph node mapping in colorectal cancer. Eur J Surg Oncol. 2010;36:130–4.PubMedCrossRef

16.

Dragan R, Nebojsa M, Dejan S, Ivan P, Dragos S, Damir J, et al. Clinical application of sentinel lymph node biopsy for staging, treatment and prognosis of colon and gastric cancer. Hepatogastroenterology. 2009;56:1606–11.PubMed

17.

Ivanov K, Kolev N, Ignatov V, Madjov R. Intraoperative sentinel lymph node mapping in patients with colorectal cancer. Hepatogastroenterology. 2009;56:99–105.PubMed

18.

Nordgard O, Oltedal S, Korner H, Aasprong OG, Tjensvoll K, Gilje B, et al. Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach. Ann Surg. 2009;249:602–7.PubMedCrossRef

19.

Van der Zaag ES, Buskens CJ, Kooij N, Akol H, Peters HM, Bouma WH, et al. Improving staging accuracy in colon and rectal cancer by sentinel lymph node mapping: a comparative study. Eur J Surg Oncol. 2009;35:1065–70.PubMedCrossRef

20.

Park JS, Chang IT, Park SJ, Kim BG, Choi YS, Cha SJ, et al. Comparison of ex vivo and in vivo injection of blue dye in sentinel lymph node mapping for colorectal cancer. World J Surg. 2009;33:539–46.PubMedCrossRef

21.

Chan SH, Ng C, Looi LM. Intraoperative methylene blue sentinel lymph node mapping in colorectal cancer. ANZ J Surg. 2008;78:775–9.PubMedCrossRef

22.

Quadros CA, Lopes A, Araujo I, Fregnani JH, Fahel F. Upstaging benefits and accuracy of sentinel lymph node mapping in colorectal adenocarcinoma nodal staging. J Surg Oncol. 2008;98:324–30.PubMedCrossRef

23.

Faerden AE, Sjo OH, Andersen SN, Hauglann B, Nazir N, Gravdehaug B, et al. Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancer. Dis Colon Rectum. 2008;51:891–6.PubMedCrossRef

24.

Lim SJ, Feig BW, Wang H, Hunt KK, Rodriguez-Bigas MA, Skibber JM, et al. Sentinel lymph node evaluation does not improve staging accuracy in colon cancer. Ann Surg Oncol. 2008;15:46–51.PubMedCrossRef

25.

Sandrucci S, Mussa B, Goss M, Mistrangelo M, Satolli MA, Sapino A, et al. Lymphoscintigraphic localization of sentinel node in early colorectal cancer: results of a monocentric study. J Surg Oncol. 2007;96:464–9.PubMedCrossRef

26.

Köksal H, Bostanci H, Mentes BB. Importance of sentinel lymph nodes in colorectal cancer: a pilot study. Adv Ther. 2007;24:583–8.PubMedCrossRef

27.

Kelder W, Braat AE, Karrenbeld A, Grond JA, De Vries JE, Oosterhuis JW, et al. The sentinel node procedure in colon carcinoma: a multi-centre study in The Netherlands. Int J Colorectal Dis. 2007;22:1509–14.PubMedCrossRef

28.

Bembenek AE, Rosenberg R, Wagler E, Gretschel S, Sendler A, Siewert JR, et al. Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg. 2007;245:858–63.PubMedCrossRef

29.

Stojadinovic A, Nissan A, Protic M, Adair CF, Prus D, Usaj S, et al. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study G1-01. Ann Surg. 2007;245:846–57.PubMedCrossRef

30.

Matter M, Winckler M, Aellen S, Bouzourene H. Detection of metastatic disease with sentinel lymph node dissection in colorectal carcinoma patients. Eur J Surg Oncol. 2007;33:1183–90.PubMedCrossRef

31.

Tiffet O, Kaczmarek D, Chambonniere ML, Guillan T, Baccot S, Prévot N, et al. Combining radioisotopic and blue-dye technique does not improve the false-negative rate in sentinel lymph node mapping for colorectal cancer. Dis Colon Rectum. 2007;50:962–70.PubMedCrossRef

32.

Van Schaik PM, Van der Linden JC, Ernst MF, Gelderman WA, Bosscha K. Ex vivo sentinel lymph node “mapping” in colorectal cancer. Eur J Surg Oncol. 2007;33:1177–82.PubMedCrossRef

33.

Murawa D, Filas V, Breborowicz J, Spychala A, Dworzecka K, Murawa P. Evaluation of the sentinel node biopsy in colorectal carcinoma including the results of immunohistochemical examinations. Acta Chir Belg. 2007;107:45–8.PubMed

34.

Liberale G, Lasser P, Sabourin JC, Malka D, Duvillard P, Elias D, et al. Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases. Gastroenterol Clin Biol. 2007;31:281–5.PubMedCrossRef

35.

Covarelli P, Cristofani R, Boselli C, Servoli A, Burattini MF, Badolato M, et al. Preliminary study on radioguided sentinel node identification in colon cancer. Am Surg. 2007;73:222–6.PubMed

36.

Bianchi PP, Ceriani C, Rottoli M, Torzilli G, Roncalli M, Spinelli A, et al. Laparoscopic lymphatic mapping and sentinel lymph node detection in colon cancer: technical aspects and preliminary results. Surg Endosc. 2007;21:1567–71.PubMedCrossRef

37.

Yagci G, Unlu A, Kurt B, Can MF, Kaymakcioglu N, Cetiner S, et al. Detection of micrometastases and skip metastases with ex vivo sentinel node mapping in carcinoma of the colon and rectum. Int J Colorectal Dis. 2007;22:167–73.PubMedCrossRef

38.

Thomas KA, Lechner J, Shen P, Waters GS, Geisinger KR, Levine EA. Use of sentinel node mapping for cancer of the colon: ‘to map or not to map.’ Am Surg. 2006;72:606–11.PubMed

39.

Terwisscha Van Scheltinga SE, Den Boer FC, Pijpers R, Meyer GA, Engel AF, Silvis R, et al. Sentinel node staging in colon carcinoma: value of sentinel lymph node biopsy with radiocolloid and blue staining. Scand J Gastroenterol Suppl. 2006;243:153–7.PubMedCrossRef

40.

Smith J, Hwang H, Wiseman KW, Filipenko D, Phang PT. Ex vivo sentinel lymph node mapping in colon cancer: improving the accuracy of pathologic staging? Am J Surg. 2006;191:665–8.PubMedCrossRef

41.

Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, et al. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg. 2006;191:305–10.PubMedCrossRef

42.

Tuech JJ, Pessaux P, Di Fiore F, Nitu V, Lefebure B, Colson A, et al. Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach. Eur J Surg Oncol. 2006;32:158–61.PubMedCrossRef

43.

Khafagy W, El-Dawoody A, El-Ghawalby N, El-Shobaky M, Atwan N. Ultrastaging of rectal cancer based on identification of micrometastases in sentinel lymph node. Coloproctology. 2005;27:153–60.CrossRef

44.

Codignola C, Zorzi F, Zaniboni A, Mutti S, Rizzi A, Padolecchia E, et al. Is there any role for sentinel node mapping in colorectal cancer staging? Personal experience and review of the literature. Jpn J Clin Oncol. 2005;35:645–50.PubMedCrossRef

45.

Braat AE, Oosterhuis JW, Moll FC, de Vries JE, Wiggers T. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg. 2005;92:1533–8.PubMedCrossRef

46.

Smith FM, Coffey JC, Khasri NM, Walsh MF, Parfrey N, Gaffney E, et al. Sentinel nodes are identifiable in formalin-fixed specimens after surgeon-performed ex vivo sentinel lymph node mapping in colorectal cancer. Ann Surg Oncol. 2005;12:504–9.PubMedCrossRef

47.

Dahl K, Westlin J, Kraaz W, Winqvist O, Bergkvist L, Thörn M. Identification of sentinel nodes in patients with colon cancer. Eur J Surg Oncol. 2005;31:381–5.PubMedCrossRef

48.

Bell SW, Mourra N, Flejou JF, Parc R, Tiret E. Ex vivo sentinel lymph node mapping in colorectal cancer. Dis Colon Rectum. 2005;48:74–9.PubMedCrossRef

49.

Bertagnolli M, Miedema B, Redston M, Bem J, Dowell J, Niedzwiecki D, Fleshman J, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004;624:628–30.

50.

Demirbas S, Ince M, Baloglu H, Celenk T. Should sentinel lymph node mapping be performed for colorectal cancer? Turk J Gastroenterol. 2004;15:39–44.PubMed

51.

Wong JH, Johnson DS, Namiki T, Tauchi-Nishi P. Validation of ex vivo lymphatic mapping in hematoxylin–eosin node negative carcinoma of the colon and rectum. Ann Surg Oncol. 2004;11:772–7.PubMedCrossRef

52.

Patten LC, Berger DH, Rodriquez-Bigas M, Mansfield P, Delpassand E, Cleary KR, et al. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping. Cancer. 2004;15:2104–9.CrossRef

53.

Bembenek A, Rau B, Moesta T, Markwardt J, Ulmer C, Gretschel S, et al. Sentinel lymph node biopsy in rectal cancer: not yet ready for routine clinical use. Surgery. 2004;135:498–505.PubMedCrossRef

54.

Bertoglio S, Sandrucci S, Percivale P, Goss M, Gipponi M, Moresco L, et al. Prognostic value of sentinel lymph node biopsy in the pathologic staging of colorectal cancer patients. J Surg Oncol. 2004;85:166–70.PubMedCrossRef

55.

Roseano M, Scaramucci M, Ciutto T, Balani A, Turoldo A, Zanconati F, et al. Sentinel lymph node mapping in the management of colorectal cancer: preliminary report. Tumori. 2003;89:412–6.PubMed

56.

Viehl CT, Hamel CT, Marti WR, Guller U, Eisner L, Stammberger U, et al. Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size. World J Surg. 2003;27:1285–90.PubMedCrossRef

57.

Bilchik AJ, Nora DT, Sobin LH, Turner RR, Trocha S, Krasne D, et al. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol. 2003;21:668–72.PubMedCrossRef

58.

Broderick-Villa G, Ko A, O’Connell TX, Guenther JM, Danial T, DiFronzo LA. Does tumor burden limit the accuracy of lymphatic mapping and sentinel node biopsy in colorectal cancer? Cancer J. 2002;8:445–50.PubMedCrossRef

59.

Kitagawa Y, Watanabe M, Hasegawa H, Yamamoto S, Fujii H, Yamamoto K, et al. Sentinel node mapping for colorectal cancer with radioactive tracer. Dis Colon Rectum. 2002;45:1476–80.PubMedCrossRef

60.

Nastro P, Sodo M, Dodaro CA, Gargiulo S, Acampa W, Bracale U, et al. Intraoperative radiochromoguided mapping of sentinel lymph node in colon cancer. Tumori. 2002;88:352–3.PubMed

61.

Paramo JC, Summerall J, Poppiti R, Mesko TW. Validation of sentinel node mapping in patients with colon cancer. Ann Surg Oncol. 2002;9:529–31.CrossRef

62.

Cox ED, Kellicut D, Adair C, Marley K, Otchy DP, Peoples GE. Sentinel lymph node evaluation is technically feasible and may improve staging in colorectal cancer. Curr Surg. 2002;59:301–6.PubMedCrossRef

63.

Gandy CP, Biddlestone LR, Roe AM, O’Leary DP. Intra-operative injection of patent blue V dye to facilitate nodal staging in colorectal cancer. Colorectal Dis. 2002;4:447–9.PubMedCrossRef

64.

Esser S, Reilly WT, Riley LB, Eyvazzadeh C, Arcona S. The role of sentinel lymph node mapping in staging of colon and rectal cancer. Dis Colon Rectum. 2001;44:850–4.PubMedCrossRef

65.

Merrie AE, van Rij AM, Phillips LV, Rossaak JI, Yun K, McCall JL. Diagnostic use of the sentinel node in colon cancer. Dis Colon Rectum. 2001;44:410–7.PubMedCrossRef

66.

Cserni G, Vajda K, Tarjan M, Bori R, Svebis M, Baltas B. Nodal staging of colorectal carcinomas from quantitative and qualitative aspects. Can lymphatic mapping help staging? Pathol Oncol Res. 1999; 5:291–6.PubMedCrossRef

67.

Joosten JJ, Strobbe LJ, Wauters CA, Pruszczynski M, Wobbes T, Ruers TJ. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg. 1999;86:482–6.PubMedCrossRef

68.

Cahill RA, Leroy J, Marescaux J. Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature. BMC Surg. 2008;24:8–17.

69.

Nissan A, Protic M, Bilchik A, Eberhardt J, Peoples GE, Stojadinovic A. Predictive model of outcome of targeted nodal assessment in colorectal cancer. Ann Surg. 2010;251:265–74.PubMedCrossRef

70.

Van der Pas MH, Meijer S, Hoekstra, Riphagen II, de Vet HC, Knol DL, et al. Sentinel-lymph-node procedure in colon and rectal cancer: a systematic review and meta-analysis. Lancet Oncol. 2011;12:540–50.PubMedCrossRef

71.

Cahill RA, Bembenek A, Sirop S, Waterhouse DF, Schneider W, Leroy J, et al. Sentinel node biopsy for the individualization of surgical strategy for cure of early-stage colon cancer. Ann Surg Oncol. 2009;16:2170–80.PubMedCrossRef

72.

De Wijkerslooth TR, De Haan MC, Stoop EM, Deutekom M, Fockens P, Bossuyt PM, et al. Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial. BMC Gastroenterol. 2010;10;47.PubMedCrossRef

73.

Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al. UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–33.PubMedCrossRef

74.

Van der Zaag ES, Kooij N, Van de Vijver MJ, Bemelman WA, Peters HM, Buskens CJ. Diagnosing occult tumour cells and their predictive value in sentinel nodes of histologically negative patients with colorectal cancer. Eur J Surg Oncol. 2010;36:350–7.PubMedCrossRef

75.

Bukholm IR, Bondi J, Wiik P, Nesland JM, Andersen SN, Bakka A, et al. Presence of isolated tumour cells in mesenteric lymph nodes predicts poor prognosis in patients with stage II colon cancer. Eur J Surg Oncol. 2003;29:862–6.PubMedCrossRef

76.

Cristofanili M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRef

77.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.PubMedCrossRef

78.

Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713–8.PubMedCrossRef

79.

Messerini L, Cianchi F, Cortesini C, Comin CE. Incidence and prognostic significance of occult tumor cells in lymph nodes from patients with stage IIA colorectal carcinoma. Hum Pathol. 2006;37:1259–67.PubMedCrossRef

80.

Hashiguchi Y, Hase K, Ueno H, Mochizuki H, Kajiwara Y, Ichikura T, et al. Prognostic significance of the number of lymph nodes examined in colon cancer surgery. Ann Surg. 2010;251:872–81.PubMedCrossRef

81.

Van der Zaag ES, Bouma WH, Peters HM, Bemelman WA, Buskens CJ. Implications of sentinel lymph node mapping for nodal staging and prognosis in colorectal cancer. Colorectal Dis. 2012;14:684–90.PubMedCrossRef

Titel: Systematic Review of Sentinel Lymph Node Mapping Procedure in Colorectal Cancer
verfasst von: Edwin S. van der Zaag, MD, PhD
Wim H. Bouma, MD, PhD
Pieter J. Tanis, MD, PhD
Dirk T. Ubbink, MD, PhD
Willem A. Bemelman, MD, PhD
Christianne J. Buskens, MD, PhD
Publikationsdatum: 01.10.2012
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 11/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2417-0

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2012

Definition of T3/4 and Regional Lymph Nodes in Gallbladder Cancer: Which Is More Valid, the UICC or the Japanese Staging System?

The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection

Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells

Integrating Bioinformatics and Clinicopathological Research of Gastrointestinal Stromal Tumors: Identification of Aurora Kinase A as a Poor Risk Marker

Upper Transversal Hepatectomy

Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study

Update Chirurgie